Do you modify your radiation planning approach or OAR dose constraints for a patient with stage IIB–IIIB NSCLC who has already received neoadjuvant immunotherapy before proceeding to definitive CRT?

I have not modified the radiation planning approach in this situation. I still treat residual PET-positive disease with customary CTV and PTV margins, motion management, etc. The only difference here is using a shorter course of radiation for some patients who are not getting concurrent chemotherapy...

For a patient with locally advanced NSCLC who receives induction chemo-IO and then does not proceed to surgery, I typically use the post-induction tumor volume as the GTV for contouring, in terms of target size. However, if there were nodal levels involved that have completely resolved during induct...